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Abstract	
Survival for childhood central nervous system (CNS) tumours varies across Europe, partly because 
of the difficulty of distinguishing malignant from non-malignant disease. This study examines bias 
in CNS tumours survival analysis to obtain the reliable and comparable survival figures. 
We analysed survival data for about 15,000 children (age <15) diagnosed with CNS between 2000 
and 2007, from 71 population-based cancer registries in 27 countries. We selected high-quality data 
based on registry-specific data quality indicators and recorded observed 1-year and 5-year survival 
by countries and CNS entity. 
We provided age-adjusted survival and used a Cox model to calculate the hazard ratios (HRs) of 
death, adjusting by age, site and grading by country. 
Recording of non-malignant lesions, use of appropriate morphology codes and completeness of life 
status follow-up differed among registries. Five-year survival by countries varied less when non-
malignant tumours were included, with rates between 79.5% and 42.8%. The HRs of dying, for 
registries with good data, adjusting by age and grading, were between 0.7 and 1.2; differences were 
similar when site (supra- and infra-tentorial) was included. 
Several sources of bias affect the correct definition of CNS tumours, the completeness of incidence 
series and the goodness of follow-up. The European Network of Cancer Registries needs to improve 
childhood cancer registration and stress the need to update the International Classification for 
Cancer. Since survival differences persisted even when restricting the analysis to registries with 
satisfactory data, and since diagnosis of CNS tumours is difficult and treatment complex, national 
plans must aim for the revision of the diagnosis and the coordination of care, with adequate national 
and international networks. 
1.	Introduction	
The central nervous system (CNS) is the most common site of solid tumours affecting children [1]. 
Five-year survival of children with malignant CNS tumours in Europe in 2005–2007 was 58%, 
from 54% in Eastern regions and the UK and Ireland to 65% in the North [2]. There is presumably 
ample room for improvement in regions with low survival. However, data on CNS tumours 
collected by European population-based cancer registries (CRs) are not completely comparable. In a 
previous analysis of European childhood cancer survival, the differences in registration criteria 
were so extensive that CNS tumours had to be removed from the analysis of all childhood cancers 
combined for reliable comparison of survival across countries [2]. 
We analysed the main sources of bias in childhood CNS tumour survival across Europe, 
considering the completeness of incidence series, standardisation of the definition of disease 
entities, the collection and completeness of benign and borderline lesions, and the quality of follow-
up. The major aim was to produce more reliable survival figures for CNS tumours by country, 




The EUROCARE-5 database [2] covers about 38,000 CNS tumours, defined as group III in the 
International Classification of Childhood Cancers, third edition (ICCC-3) [3], diagnosed in 
European children aged 0–14 years from 1-Jan-1978 to 31-Dec-2007, with vital status updated to 
31-Dec-2008. We obtained data from 71 population-based CRs in 27 countries (Table 1). Most 
countries had national cancer registration. All registries sent data for anonymous central analysis 
according to a standardised protocol [4]. 
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Denmark 0 0.0 0.0 0.0 264 83.0 0.0 51.9 18.6 n.a – n.a 
Finland 0 0.0 0.0 0.0 292 97.3 0.0 23.6 3.8 45.6 5 0 
Norway 0 0.0 0.0 0.0 335 84.2 0.0 48.1 10.4 6.9 12 16.7 (0.2–41)
UK and 
Ireland 
Ireland 1 0.4 0.0 0.0 224 79.5 0.0 37.9 4.0 10.3 8 25.0 (4–56) 
UK–




Ireland 0 0.0 0.0 0.0 103 71.8 0.0 41.7 27.2 1.0 5 0 
UK–Scotland 1 0.0 0.4 0.0 245 76.3 0.0 44.1 8.2 7.4 14 0 
Central 
Europe 
Austria 0 0.0 0.0 0.0 349 95.7 0.0 25.2 4.0 7.7 45 24.1 (13–38) 
Belgium 5 0.0 0.0 1.7 295 94.9 0.0 34.6 2.7 3.4 27 12.2 (2–33) 
France 5 0.0 0.0 0.2 3156 85.6 3.7 43.6 1.5 7.3 219 17.9 (13–24) 
Germany 39 0.0 0.0 1.2 3315 87.5 27.1 40.4 1.3 6.1 398 19.4 (15–24) 
Switzerland 2 0.0 1.3 1.3 84 89.3 10.5 41.7 10.7 1.2 6 0 
The 





Croatia 2 0.8 0.0 0.0 260 73.1 0.0 26.2 35.0 4.2 14 40.8 (16–65) 
Italy 1 0.1 0.0 0.0 825 77.2 1.3 37.1 17.3 5.3 53 28.6 (17–42) 
Malta 2 9.5 0.0 0.0 19 84.2 0.0 26.3 0.0 5.3 3 33.3 (1–77) 
Portugal 1 0.0 0.0 0.3 292 88.4 2.0 25.4 4.5 10.3 20 10.0 (2–27) 
Slovenia 0 0.0 0.0 0.0 64 96.9 0.0 34.4 4.7 3.1 10 50.0 (18–75) 
Spain 3 0.0 0.0 0.5 579 75.9 1.6 29.3 8.6 10.2 22 32.7 (13–54) 
Eastern 
Europe 
Bulgaria 24 11.6 0.0 0.0 183 82.5 0.0 9.3 17.5 1.6 15 20.0 (5–42) 
Estonia 0 0.0 0.0 0.0 61 77.1 0.0 37.7 21.3 0.0 1 0 
Hungary 0 0.0 0.0 0.0 481 93.8 2.5 34.3 0.4 7.7 21 11.7 (2–30) 
Latvia 12 12.2 2.4 0.0 70 71.4 0.0 1.4 28.6 2.9 8 70.9 (25–92) 
Lithuania 3 3.7 0.0 0.0 79 89.9 30.8 7.6 12.7 2.5 7 0 
Poland 4 0.0 0.0 2.6 149 79.9 6.4 5.4 20.1 4.7 13 26.4 (7–52) 
Slovakia 6 1.7 0.9 0.0 228 88.6 0.0 42.1 9.6 1.8 6 33.3 (5–68) 
European pool 126 0.3 0.1 0.4 15,281 87.2 8.4 38.5 5.6 7.5 1219 
 
MV, microscopic verification; DCO, death certificate only; CNS, central nervous system; CI, confidence interval; ICD-O M, International 
Classification of Diseases for oncology third edition; n.a., not available; ICCC, International Classification of Diseases for Oncology, third edition. 
In bold type countries with national coverage; partial coverage for Belgium (56%), Switzerland (29%), Italy (36%), Portugal (70%), Spain (34%), 
Poland (12%). 
aNot correctable errors after consistency check. 
bNumber of patients alive followed for less than five years out of all patients diagnosed in 2000–2003 alive before or at five years. 
cGlioma NOS (in all sites excluding optic nerve). 
dAtypical teratoid/rhabdoid tumour (ICD-O M 9508/3), anaplastic astrocytoma (ICD-O M 9401/3), anaplastic oligodendroglioma (ICD-O M 9451/3) 
and glioblastoma (ICD-O M 9440/3-9442/3). 
Table 2. CNS childhood tumours diagnosed in 2000–07: incidence rates (IRs) and 1- and 5-year survival with 95% confidence interval (CI) by 
country and tumour behaviour. 
Country 


































Denmark 80.3 72–86 60.6 
51–









Finland 86.1 81–90 75.3 
69–









Norway 84.5 78–89 62.5 
54–









Ireland 77.0 69–83 59.7 
50–





































UK–Scotland 72.3 64–79 52.2 
43–









Austria 81.6 76–86 63.8 
57–
70 2.5 100  94.2 
85–





Belgium 76.2 70–82 64.1 
57–









France 73.1 71–75 51.8 
49–









Germany 79.9 78–82 59.1 
57–









Switzerland 73.5 59–84 57.8 
42–



















Croatia 88.0 83–92 69.6 
62–









Italy 80.8 77–84 61.3 
57–









Malta 78.6 47–93 61.2 
29–





Portugal 74.1 68–79 53.4 
46–









Slovenia 78.6 63–88 57.2 
40–





Spain 81.8 78–85 62.1 
57–









Bulgaria 55.4 48–63 38.1 
30–









Estonia 76.3 59–87 61.1 
43–









Hungary 75.5 70–80 55.1 
49–









Latvia 81.2 70–89 65.6 
53–





Lithuania 77.6 65–86 49.2 
36–





Poland 85.7 79–91 61.7 
52–
70 2.2 100  70 
23–





Slovakia 74.2 66–81 52.7 
43–









European pool 77.1 76– 57.1 56– 2.2 96.7 96– 94.4 94– 1.4 84.7 84– 71.3 71– 3.5
Country 


































78 58 97 95 85 72 
ƿ = 0.64, P < 0.001 ƿB = −0.002, P = 0.99 ƿB = 0.12, P = 0.42 
CNS, central nervous system. 
ƿB calculated excluding Austria, Finland, Bulgaria, Latvia, Lithuania and Poland because of incomplete collection of non-malignant cases. 
a IR are calculated per 100,000 per year. 
 
Tumours were grouped into the six categories defined by ICCC-3, group III [3], [5]. The 
EUROCARE-5 protocol [4] asked registries to include both malignant tumours (5th digit in the 
morphology code equal to 3 in the International Classification of Diseases for Oncology third 
edition, ICD-O M) and tumours with non-malignant behaviour (5th digit in the morphology codes: 
0 or 1). However, some registries communicated to have an incomplete collection of non-malignant 
tumours (Austria, Bulgaria, Finland, Latvia, Lithuania and Poland). 
To analyse survival differences between countries, we had to check the quality of data. For CNS 
tumour, most important indicators of data quality were: the proportions of unspecified intracranial 
and intraspinal neoplasms—ICCC-3-IIIf; the proportion of glioma NOS (M-9380/2-3, excluding 
optical nerve); the proportion of non-malignant tumours, which may suggest, if too low, incomplete 
registration; the 5-year survival of CNS tumours with very bad prognosis—atypical 
teratoid/rhabdoid tumours (M-9508/3), anaplastic astrocytoma (M-9401/3), anaplastic 
oligodendroglioma (M-9451/3) and glioblastoma (M-9440/3-9442/3) which, if higher than average, 
suggests errors in follow-up. 
2.2.	Data	analysis	
Observed survival was calculated by the actuarial method. Survival was analysed on a data set 
containing all childhood cases diagnosed between 1-Jan-2000 and 31-Dec-2007 and followed up 
until 31-Dec-2008. Survival for 2000–07 was estimated using the complete approach [6]. This is 
similar to the cohort method but includes recently diagnosed patients (e.g. 2004–2007) with <5 
years of follow-up. To ensure comparability between countries, age-standardised country-specific 
5-year survivals were also provided. We standardised the estimates to the age distribution of all 
European children 2000–2007 diagnosed with CNS tumours, defining four classes (<1, 1–4, 5–9 
and 10–14 years) [2]. We calculated the crude annual incidence rates (IRs) per 100,000 by country 
and used Pearson's correlation coefficient (ƿ) to relate these to 5-year survival. 
We used a Cox model [7] to calculate the hazard ratios of death (HRs) by country and their 95% 
confidence intervals (95%CI), according to age, sex, subsite and grading (based on the fourth 
edition of the WHO classification, which assigned a grade to each ICD-O M, see Table 3) [8]. To 
adjust for grading, we divided all the tumours as follows: grade I, grade II, grade III–IV, 
unspecified tumours with non-malignant behaviour, unspecified tumours with malignant behaviour, 
astrocytoma NOS, glioma NOS (excluding optic nerve). As for the few ICD-O morphological 
entities not considered in the WHO classification, benign meningioma, pituitary tumour, 
gliofibroma, choroid glioma, and astroblastoma (even if occasionally it may have an aggressive 
course), were placed with grade I tumours, and gliomatosi cerebri with grades III–IV. 
Table 3. Five-year survival and 95% confidence interval (CI) for children with non-malignant or malignant CNS tumours diagnosed in 2000–07 in 










1534 10.2 98.9 70 67–72
 
 Choroid plexus papilloma  I  172 11.2 97.6 97 92–99 9390/0 
 Subependymoma  I  20 1.3 80 95 65–99 9383/1 
 Myxopapillary ependymoma  I  75 4.9 100 96 85–99 9394/1 
 Atypical choroid plexus papilloma  II  35 2.3 100 89 69–97 9390/1 
 Ependymoma, other and NOS  II  591 38.5 99 70 66–74 9391/3, 9393/3 
 Choroid plexus carcinoma  III  150 9.8 98 44 36–53 9390/3 
 Anaplastic ependymoma  III  491 32 100 61 56–66 9392/3 
IIIb astrocytomas 
 
6078 40.5 91.5 80 79–81
 
 Pilocytic astrocytoma  I  3231 53.2 98.9 95 94–96 9421/1 
 Subependymal giant cell astrocytoma I  136 2.2 92.7 99 97–99 9384/1 
 Glioma, optic nerve  I  611 10.1 36.5 99 97–99 9380/3 
 Pleomorphic xanthoastrocytoma  II  73 1.2 100 85 74–92 9424/3 
 Fibrillary astrocytoma  II  182 3.0 97.8 75 67–81 9420/3 
 Protoplasmic astrocytoma  II  19 0.2 100 95 68–99 9410/3 
 Gemistocytic astrocytoma  II  8 0.1 87.5 41 7–74 9411/3 
 Anaplastic astrocytoma  III  338 5.6 99.7 21 16–26 9401/3 
 Glioblastoma and variants  IV  530 8.7 98.7 14 11–18 9440/3, 9441/3, 9442/3 
 Astrocytomas, NOS  –  948 15.5 92.7 74 71–77 9400/3, 9423/3 





3097  20.7 99.2  57  55–59
 
 Medulloblastoma, variants  IV  2006  64.8 99.4  65  62–67 9470/3, 9472/3, 9480/3, 9501/3, 
9503/3 
 Medulloblastoma large cell  IV  52 1.7 100 36 17–56 9474/3 
 Desmoplastic/nodular medulloblastoma  IV  237 7.6 99.6 72 65–78 9471/3 








 Atypical teratoid/rhabdoid tumour  IV  258 8.3 99.2 23 18–29 9508/3 
IIId Other gliomas 
 
1642 10.9 66.1 46 43–49
 
 Oligodendroglioma  II  212 12.9 98.1 74 67–80 9450/3,9460/3 
 Oligodendroglioma, anaplastic  III  91 5.6 98.9 30 20–40 9451/3 
 Glioma, mixed  III  137 8.4 99.3 54 45–62 9382/3 
 Astroblastoma  –  19 1.2 100 78 53–92 9430/3 
 Chordoid glioma  –  1 0.1 100
   
9444/1 
 Gliomatosi cerebri  –  30 1.8 86.7 32 16–49 9381/3 
 Glioma NOS (excl.optic nerve)  –  1152 70.2 53 41 38–44 9380/3 
IIIe Other specified CNS tumours 
 
1866 12.4 93 93 91–94
 
 Pinealoma and pineocytoma  I  19 1.0 73.7 89 43–98 9360/1, 9361/1 
 Desmoplastic infantile astrocytoma  I  59 3.2 98.5 85 73–92 9412/1 
 Dysembryoplastic neuroepithelial tumour  I  322  17.3 88.5  99  97–
100  9413/0 
 Gangliocytomas, ganglioglioma  I  402 21.6 96.8 96 93–98 9492/1, 9505/1, 9493/1 
 Meningioma, non‐malignant  I  188 10.1 92.5 95 87–96 9530/0, 9530/1, 9531/0‐9539/1
 Craniopharyngioma  I  608 32.5 93.8 97 96–99 9350/1, 9351/1, 9352/1 
 Central neurocytoma  II  17 0.9 100 88 61–97 9506/1 
 Ganglioglioma, anaplastic  III  25 1.3 100 70 48–85 9505/3 
 Meningioma, malignant  III  29 1.6 100 79 58–90 9530/3,9538/3,9539/3 
 Pineoblastoma  IV  105 5.6 100 46 35–56 9362/3 





800 5.3 17.9 64 60–67
 
 Malignant  –  429 53.4 15.2 51 46–56 8000/3‐8005/3 
 Benign  –  371 46.6 21 78 74–82 8000/0,1‐8005/0 
CNS, central nervous system; MV, microscopically verified. 
Includes number of cases, proportion of microscopically verified cases and proportion of cancer cases for each diagnostic group. The column headed 
‘ICDO3-M’ lists all the histological ICD0-3 codes in our Data Base different from 0. In this table, we excluded the cases from Denmark. 
aInternational Classification of Diseases for Oncology, third edition. 
The conventional two-sided 5% level was chosen as the threshold for statistical significance. The 
statistical analyses were performed with STATA [9] and SEER*stat software. 
3.	Results	
The data provided, by contributing country, including the basic and specific data quality indicators, 
are summarised in Table 1. After removing 126 cases known to the registries from death certificate 
only (DCO) or autopsy, or with no information on follow-up, we finally analysed 15,281 diagnoses 
of CNS tumours. The proportion of DCO was 0.3% overall, and less than 1% in most countries. 
High DCO rates in Malta, Bulgaria and Latvia were explained by 2, 24 and 10 cases. In all, 87% of 
childhood CNS tumours had microscopic verification (MV), ranging from 71 to 72% in Northern 
Ireland and Latvia to 97% in Finland and Slovenia. The proportion of cases censored before five 
years of follow-up, among 2000–2003 diagnosed cases still alive, was less than 4% in all countries 
except Lithuania (31%), Germany (27%), Switzerland (10%) and Poland (6%). DCO and Autoptic 
cases did not enter in the survival analyses, whereas censored cases contributed with their period of 
observation and then exited as ‘censored’. 
There was 39% of non-malignant tumours, but with wide differences from <10% to >40%. Table 1 
also includes the proportion of CNS tumours with morphologies not specified: the ICCC IIIf-
unspecified intracranial and intraspinal tumours (UNSP, 6% of all CNS tumours) and glioma NOS 
(ICD-O M 9380/3, optic nerve excluded, 8%). The proportion of UNSP was mostly below 10%, but 
high proportions (>20%) were registered in Northern Ireland, Latvia, Estonia, Poland and Croatia. 
The proportions of glioma NOS were mostly <10%, lower for countries with high UNSP, and 
higher for those without. Finland, however, had a very high proportion of glioma NOS. 
As an indicator of completeness of follow-up across countries, we report 5-year survival for highly 
lethal tumours (anaplastic astrocytoma, glioblastomas, anaplastic oligodendroglioma and atypical 
teratoid/rhabdoid tumour) which were 8% of all CNS tumours. Too high survival figures suggest 
difficulties in access to death certificates or administrative sources, so some patients are wrongly 
considered alive only because the death certificates did not reach the registries or did not match the 
cases, or the patients become untraceable [10]. Slovenia, Latvia and Croatia had high 5-year 
survival (≥40%), although with wide 95%CIs. Five-year survival in Europe for this group of 
tumours was 19% (not in Table). Unfortunately, Denmark coded CNS tumour morphologies in few 
generic groups (Neoplasm NOS, Ependymoma NOS, Astrocytoma NOS, Glioma malignant NOS, 
Medulloblastoma NOS and Ganglioglioma NOS), so we could not estimate some quality indicators 
in Table 1. 
Table 2 shows 1- and 5-year survival by country for malignant and non-malignant tumours and for 
all the tumours combined, with their IRs per 100,000/year. Five-year survival of malignant tumours 
averaged 57% in Europe, from 75% in Finland to 38% in Bulgaria. Non-malignant tumours had 
high 5-year survival rates (94% on average), between 100% and 85%, except Estonia, Portugal and 
Poland. For all CNS tumours, survival reached 71% in Europe and the variability decreased, 
particularly among non-Eastern European countries. There were no longer any differences in 
survival within Northern Europe and the UK and Ireland when non-malignant lesions were 
included. For Central and Southern Europe, differences dropped: 5-year survival was ≥70% in all 
except Netherlands (67%) and Portugal (61%). For Eastern Europe, Bulgaria, Latvia, Lithuania and 
Poland, with incomplete registration of non-malignant cases, had low survival (<66%), whereas for 
Estonia, Slovakia and Hungary, which registered non-malignant cases, survival was 70%, 72% and 
68%, respectively. Survival in all regions dropped steeply after the first year from diagnosis, so 
there were large gaps between 1- and 5-year survival. 
The annual IRs (per 100,000/year) of CNS malignant tumours were between 1.6 and 3. The rates 
for all CNS tumours combined were highest (≥4) in Finland, Croatia and Norway. Rates between 3 
and 4 were also reported from all UK and Ireland, and for most of the countries in Southern and 
Central European countries. 
There was a relation between incidence and survival of malignant tumours by country: the higher 
the incidence, the better the survival (ƿ = 0.6; P < 0.001). A relation between incidence and survival 
of all CNS cases was not found, when including only registries that had a complete registration of 
non-malignant tumours (Table 2). 
Five-year survival rates by histotype within the six ICCC groups varied widely both between and 
within the main groups (Table 3). In the category of ependymomas and variant (IIIa), the choroid 
plexus carcinomas had the lowest survival (44%); non-malignant tumours, 20% of all IIIa cases had 
survival >89%. Astrocytomas (IIIb) included 14% of anaplastic astrocytomas and glioblastomas, 
with poor survival 21% and 14%. Pilocytic astrocytoma, 53% of IIIb group, and optic nerve glioma, 
had both very high outcome (95% and 99%). Sixty-five percent of embryonal tumours (ICCC IIIc) 
were medulloblastoma with 65% five-year survival. Eighteen percent were other PNET with worse 
survival (41%). A small proportion of IIIc were atypical teratoid/rhabdoid tumours, with poor 
survival (23%). 
Seventy percent of ‘other gliomas’ (IIId) were glioma NOS (optic nerve excluded) with 41% 5-year 
survival. ICCC IIIe ‘other specified CNS tumours’ consisted mainly of non-malignant tumours with 
very good prognosis, except pinealoblastoma. The ‘unspecified tumours of the CNS’ (IIIf) were 
half non-malignant and half malignant. 
Table 4 shows 5-year survival of grades I and III–IV CNS tumours by country. For grade I, survival was >90%, except Bulgaria, Portugal and Poland. 
Grades III–IV had poor survival (49%), with larger differences across countries, from <40% in Bulgaria, Lithuania and Netherlands to >60% in 
Finland, Switzerland, Austria, Croatia and Slovenia. Overall, 5-year survival for grade II was 74%, 46% for grade III and 51% for grade IV (not 
shown). 
Table 4. Five-year survival and 95% confidence interval (CI) for children with non-malignant or malignant CNS tumours diagnosed in 2000–07 by 
country and grade. 
Country 
WHO grade I tumoursa  WHO grade III and IV tumoursb




Norway  134  94.4  89–97 96 54.2 43–64
Ireland  96  90.3  81–95 54 52.1 37–65
UK–England/Wales  1017  96  94–97 757 46 42–50
UK–Northern Ireland 29  96.6  78–100 28 49.7 29–68
UK–Scotland  101  94.4  87–98 75 44 31–56
Austria  91  94.4  85–98 147 60.1 51–68
Belgium  119  94.9  89–98 106 50.8 40–60
France  1488  96.4  95–97 1011 46.9 44–50
Country 
WHO grade I tumoursa  WHO grade III and IV tumoursb
Number  Five‐year survival (%)  95% CI Number Five‐year survival (%) 95% CI




The Netherland  359  95.9  93–98 294 39.8 38–46
Croatia  37  94.4  79–97 75 63.2 51–73








Spain  161  93.8  88–97 163 50.1 41–59
Bulgaria  17  87.8  60–97 76 36.2 25–48
Estonia  13  92.3  57–99 23 51.4 30–70







Poland  8  70  23–92 65 53.6 39–66
Slovakia  96  97.9  92–100 60 51.4 38–64
European pool  5843  95.9  95–97 4993 49.4 48–51
CNS, central nervous system; n.e, not estimable. 
a5843 cases, 39% of all the CNS cases. 
b4993 cases, 33% of all the CNS cases. 
After excluding registries stated incomplete collection or with a proportion ≤25% of non-malignant 
cases, or presented possible classification or follow-up problems, we compared age-adjusted 5-year 
survival figures for 17 countries (Fig. 1). 
Comparing to Table 2, including all the countries, variability was lower but still present, with 
survival between 78% (Norway) and 58% (Portugal). 
Table 5 shows the HRs of dying, adjusting by age and grading, both statistically significant in univariate analysis. With England & Wales as 
reference, Netherlands had a significantly higher and Norway, Italy and Germany lower risk of dying. 
Table 5. Hazard ratio (HR) of dying and 95% confidence interval (CI) for children with non-malignant or malignant CNS tumours diagnosed in 2000–
07 by country, adjusted by age, grading (model 1), and site (supra- and infra-tentorial; model 2). 
Country 
Model 1  Model 2 
HR  95% CI  HR  95% CI 
Norway  0.70a  0.5–0.9  0.75a 0.6–0.99 
Belgium  0.92  0.7–1.2  0.95  0.7–1.3 
France  1.10  0.99–1.2 1.10  0.98–1.2 
Germany  0.85a  0.8–0.9  0.88a 0.8–0.99 
Switzerlandb  0.76  0.5–1.2  0.85  0.5–1.5 
The Netherlands  1.20a  1.03–1.4 1.22a 1.04–1.4 
Italyb  0.78a  0.6–0.9  0.79a 0.6–0.98 
Malta  0.87  0.4–2.1  1.31  0.5–3.5 
Portugalb  1.13  0.9–1.5  1.18  0.9–1.6 
Spainb  0.86  0.7–1.02 0.76a 0.6–0.9 





Northern Ireland  0.88  0.6–1.3  0.81  0.5–1.3 
Scotland  1.11  0.9–1.4  1.15  0.9–1.5 
Slovakia  0.93  0.6–1.5  0.98  0.6–1.7 
Estonia  1.04  0.9–1.3  0.99  0.8–1.2 
Hungary  1.01  0.8–1.3  0.98  0.7–1.3 





Restricting the analysis to supra- and infra-tentorial tumours (72% of all cases) and adjusting the 
model also for site, divided in two groups, the results remained the same, except Spain with 
significantly lower risk than England & Wales. The risks by country did not changed excluding 
CNS unspecified cases (UNSP, glioma NOS and astrocitoma NOS, 17% of all cases) from the 
multivariate analysis (not in table). 
4.	Discussion	
This EUROCARE analysis illustrates the difficulties in comparing survival of childhood CNS 
tumours between countries. First, there was incomplete collection of non-malignant tumours. The 
proportions of non-malignant cases were 44% in France, 41% in England & Wales and 40% in 
Germany. We can be confident about the level of completeness of these large childhood CRs, so an 
acceptable proportion of non-malignant cases should range between about 35% and 50%. Among 
the countries included in Fig. 1 and Table 5, Malta, Portugal and Spain are outliers with possible 
under registration. 
The correct classification of CNS tumours without microscopic confirmation, 13% in our study, is 
even more difficult. Nevertheless, the high proportion of microscopically verified CNS tumours 
does suggest incomplete and selective collection, as we know that part of the lesion can be 
identified by imaging only. As shown by the national childhood cancer registries, a proportion of 
microscopically verified cases higher than 90% should be considered suspicious for selective 
collection of cases. In our study, five countries were over this threshold, some of them with the 
highest (Finland) and other with low survival figures (Hungary; Table 2). 
Another problem is that the definition of malignancy according to the WHO Classification of CNS 
tumours may vary between and within countries. It is not easy to distinguish malignant from non-
malignant or low-grade from high-grade tumours. Even in a trial setting with pathological review, 
28% children with glioma were incorrectly diagnosed high grade instead of low grade [11]. Grading 
is containing a subjective component (Ellison DW et al.[14], Journal of Negative Results Biomed 
2011; 10:7), actually in entities like ependymoma, there is high variation between grading II and III 
ependymomas across countries, but no relevant survival difference. Inter-observer variability of the 
histologic features of anaplasia in CNS tumours illustrates a problem, since histology is so 
important for diagnostic and therapeutic decisions. Gilles et al.[12] suggested four histologic 
features as indispensable for brain tumour analysis: necrosis, cell density, nuclear pleomorphism 
and mitoses. It would be interesting to review a population-based sample of pathological reports of 
childhood CNS tumours, to see how often these characteristics are included in the report. Again, 
'benign' (grade I/II) lesions may behave clinically highly malignant if located in an inoperable CNS 
location (e.g. brain-stem) and vice-versa (grade IV tumours such as medulloblastoma may have 
very high survival rates based on its biological subgroup). We adjusted by localisation, but we 
could not take into account biological subgroup, because this is no contemplate in the used 
classifications [13], [14]. Therefore, classification such as ICCC should be updated, and this could 
be realised within the ENCR, possibly in agreement with SIOPE. 
Another issue can indicate low quality in disease definition: high proportions of UNSP and the use 
of unspecific codes like glioma NOS. UNSP and glioma NOS (optic nerve excluded) amounted to 
13% of all CNS tumours, with 5-year survivals between 64% and 41%. The high proportion of 
UNSP suggests low-quality disease definition and the erroneous registration of non-malignant 
tumours or not biopsied tumours among the CNS cases. Survival figures were therefore presumably 
overestimates for some countries. 
An important issue in survival comparisons is the completeness of follow-up, in terms of capturing 
all the deaths after diagnosis. In some cases, registries are aware that a patient is no longer traceable 
or require more time for completing follow-up; this is shown in the proportion of early censored 
cases, which was highest for Germany (27%) and Lithuania (31%). In other cases, no information 
reaches the registry, so these patients are classified as alive. Dealing with this involves analysing 
cancers with a very poor prognosis [15]. We studied this by comparing 5-year survival of lethal 
tumours (Table 1). If the diagnoses were correct, too high survival figures suggest difficulties in 
access to information from death certificates or administrative sources. Among countries with 
survival for lethal tumours higher than the European average, Latvia, Slovenia and Croatia had 5-
year survival of ≥40%. Again, a certain overestimation must be considered. 
The data quality problems and differences in registration practice for CNS tumours should draw the 
attention of the ENCR to the need to improve the standardisation of registry practices and criteria, 
taking account of modern diagnostic imaging procedures for tumours where MV is not always 
possible or convenient. We suggest to update the ENCR recommendation on brain tumour [5] by 
convene a new working group of expert. We are also aware about the difficulties made by the 
privacy regulations that limited the access to mortality data and in some cases also to the other 
source of data for cancer registries. Therefore, even if not specific for CNS cancer, the ENCR 
should continue to stress the solution of this problem. 
Even when restricted to the registries considered to have the most fully comparable data, survival 
analysis of childhood CNS tumours indicated some variability with, compared with England & 
Wales, a significant lower risk of dying between 30% and 15% (Norway, Germany, Italy). Since 
Germany had a high percentage of patients not yet followed for five years at the closing date of this 
study, we performed an analysis excluding all 2000–2003 diagnosed cases not followed for 5 years; 
this gave similar results, though no longer significant for Germany (not shown). The high 
proportion of censured cases in Germany may be partly related to the apparent good survival. 
Similar survival differences were reported in adult CNS tumours for Europe, same diagnosis period. 
However, variation between countries was lower than those reported for children, but with the 
Nordic and some central countries with the highest outcome [16]. 
The complexity of treating childhood CNS tumours is partly responsible for the observed great 
variability in histological classification, follow-up and registration practices. To improve this 
situation, requires much greater collaboration between the treating centres and population-based 
cancer registries and emphasises the need for quality control of pathological diagnoses for both 
treatment and registration purposes [17]. This might be best achieved through centralisation of 
diagnosis and treatment in fewer centres, linked through national networks to permit the 
continuation of therapies and clinical follow-up close to the child's home. 
International networks are also vital, especially since continuing progress in biological stratification 
of these rare tumours can support risk-adapted therapeutic stratification that will improve outcomes 
and reduce treatment-related morbidity. Since these cancers require a high level of specialisation 
and sophisticated infrastructure, close collaboration should be fostered between the Eastern 
countries and the European regions with better survival for childhood CNS tumours, also taking the 
advantage of the European Commission's call for twinning programs [18]. The implementation and 
extension of the European directive on Cross-Border Healthcare [19] is also important for European 
countries with small populations. Some of these have low-income levels, compared with the rest of 
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M. Santaquilani, A. Tavilla (Istituto Superiore di Sanità, Rome); F. Pannozzo, S. Busco (Latina 
CR); R. A. Filiberti, E. Marani (Liguria CR, IRCCS AOU SM-IST); P. Ricci (Mantova CR); C. 
Pascucci (Marche Childhood CR); M. Autelitano (Milano CR); G. Spagnoli, C. Cirilli (Modena 
CR); M. Fusco, M. F. Vitale (Napoli 3 South CR); M. Usala (Nuoro CR); F. Vitale, B. Ravazzolo 
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Clinica e Valutativa, Trento); A. Madeddu, F. Tisano (Siracusa CR); S. Maspero, A. C. Fanetti 
(Sondrio CR); P. Candela, T. Scuderi (Trapani CR); F. Stracci, F. Bianconi (Umbria CR); G. 
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Bielska-Lasota* (National Institute of Public Health-NIH, Warszawa); Portugal: G. Forjaz de 
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CR); M. J. Sanchez, D. Y. L. Chang (Granada CR, CIBERESP, ibs.Granada); C. Navarro, M. D. 
Chirlaque (Murcia CR, CIBERESP, IMIB-Arrixaca); C. Moreno-Iribas, E. Ardanaz (Navarra CR, 
CIBERESP); R. Peris-Bonet, E. Pardo Romaguera (Spanish Registry of Childhood Tumours, RETI-
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and Karolinska Institutet); Switzerland: M. Mousavi (Basel CR); C. Bouchardy, M. Usel (Geneva 
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